NASDAQ$SMMT
Summit Therapeutics Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Summit Therapeutics Inc reported a net loss of $565.7 million for the second quarter of 2025.
The company incurred significantly higher operating expenses driven by stock-based compensation and R&D activities related to ivonescimab development. Net loss increased substantially year-over-year with no revenue generated during the period.
- Net loss of $565.7 million for Q2 2025 compared to $62.9 million in Q1 2025.
- R&D expenses totaled $208.0 million, reflecting ongoing clinical trials for ivonescimab.
- G&A expenses reached $360.4 million, primarily due to $350.2 million in stock-based compensation.
- EPS of $(0.76) with 742.6 million weighted average shares outstanding.
Headline financials
Revenue & EPS history
Summit Therapeutics · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
-2.5%
Avg return
Earnings day
-0.5%
Avg return
5 days after
+6.7%
Avg return
30 days after
29%
12 / 42 earnings
Positive
+48.6%
Q1 2021
Best reaction
-18.9%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q4 2025 | +1.2% | +3.1% | +7.3% | |
| Q3 2025 | -4.6% | -8.1% | -21.1% | |
| Q1 2025 | +12.9% | -1.5% | -26.2% | |
| Q4 2024 | -14.8% | -6.5% | -10.1% | |
| Q3 2024 | -14.8% | -8.6% | -15.4% | |
| Q2 2024 | -6.2% | +7.6% | +24.8% | |
| Q1 2024 | +3.3% | +13.7% | +121.0% | |
| Q4 2023 | -18.9% | -8.5% | -30.0% | |
| Q3 2023 | -16.3% | -12.6% | +1.8% | |
| Q2 2023 | +1.7% | +13.1% | -12.0% | |
| Q1 2023 | -18.9% | -27.4% | -17.5% | |
| Q4 2022 | -2.0% | +14.5% | +0.7% | |
| Q3 2022 | -2.0% | +2.9% | +284.3% | |
| Q2 2022 | +1.9% | -2.9% | +24.0% | |
| Q1 2022 | +5.4% | -6.3% | -14.5% | |
| Q4 2021 | +8.3% | +19.0% | -25.2% | |
| Q3 2021 | -5.4% | -0.9% | -12.0% | |
| Q2 2021 | -2.2% | -7.9% | -19.8% | |
| Q1 2021 | +48.6% | +56.4% | +22.2% | |
| Q4 2020 | -4.3% | -5.2% | -12.3% | |
| Q3 2020 | -5.6% | -9.3% | +14.4% | |
| Q2 2020 | -0.9% | -5.2% | -4.3% | |
| Q4 2019 | -13.8% | +3.2% | -2.9% | |
| Q1 2020 | -2.7% | -5.1% | -11.3% | |
| Q3 2019 | -2.6% | -3.6% | +0.7% | |
| Q2 2019 | -7.4% | -9.1% | -4.6% | |
| Q1 2019 | -12.5% | -2.4% | -6.9% | |
| Q4 2018 | +4.0% | +7.4% | +8.6% | |
| Q3 2018 | -10.1% | -12.9% | +11.5% | |
| Q2 2018 | -2.6% | -4.3% | -19.7% | |
| Q1 2018 | -1.4% | -4.4% | -81.8% | |
| Q3 2017 | -3.0% | -2.9% | -6.2% | |
| Q2 2017 | +4.3% | +3.0% | -2.5% | |
| Q1 2017 | +4.9% | +2.9% | +15.9% | |
| Q4 2016 | -2.2% | +1.2% | -15.6% | |
| Q3 2016 | -4.5% | -6.3% | +4.7% | |
| Q2 2016 | -7.3% | -6.1% | +78.7% | |
| Q1 2016 | -4.9% | — | — | |
| Q3 2015 | +1.9% | — | — | |
| Q2 2015 | -0.9% | — | — | |
| Q1 2015 | -4.3% | — | — | |
| Q4 2014 | -4.3% | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro